Financial accounts reports

In this: publication
By this: publisher
In this Subject: Biotechnology
By this author: Aaronson, Colin

Author: Aaronson, Colin

Source: Journal of Commercial Biotechnology, Volume 11, Number 1, 1 October 2004 , pp. 97-99(3)

Buy & download fulltext article:

Price: $43.00 plus tax (Refund Policy)

Abstract:

Cambridge Antibody Technology plc (CAT) has established itself as a leader in the development of human monoclonal antibodies as new treatments for disease, based upon its own antibody technology. By mid-June 2004 it had one drug, HUMIRA^TM, a treatment for rheumatoid arthritis, approved in 41 countries including the USA and the UK, drug treatments for five conditions in Phase III and a number of other drugs at Phase I or II, or at the preclinical stage.Journal of Commercial Biotechnology (2004) 11, 97-99; doi:10.1057/palgrave.jcb.3040106

Document Type: Research article

DOI: http://dx.doi.org/10.1057/palgrave.jcb.3040106

Publication date: 2004-10-01